APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 188 filers reported holding APELLIS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,387 | +1069.7% | 40,641 | +316.9% | 0.03% | +575.0% |
| Q2 2023 | $888 | +38.1% | 9,749 | 0.0% | 0.00% | +33.3% |
| Q1 2023 | $643 | +27.6% | 9,749 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $504 | -99.9% | 9,749 | 0.0% | 0.00% | -25.0% |
| Q3 2022 | $666,000 | +51.0% | 9,749 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $441,000 | -10.9% | 9,749 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $495,000 | +7.4% | 9,749 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $461,000 | +43.6% | 9,749 | 0.0% | 0.00% | +100.0% |
| Q3 2021 | $321,000 | -47.9% | 9,749 | 0.0% | 0.00% | -66.7% |
| Q2 2021 | $616,000 | +47.4% | 9,749 | 0.0% | 0.00% | +50.0% |
| Q1 2021 | $418,000 | -25.1% | 9,749 | 0.0% | 0.00% | -33.3% |
| Q4 2020 | $558,000 | +89.8% | 9,749 | 0.0% | 0.00% | +50.0% |
| Q3 2020 | $294,000 | -7.5% | 9,749 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $318,000 | +21.8% | 9,749 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $261,000 | – | 9,749 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |